Abstract. Prolactin (Prl) 
hypothalamic lesions (HL), as assessed on clinical, radiological and surgical grounds, underwent on separate occasions acute testing with the opioid peptide FK 33-824 (0.5 mg iv), the indirect dopamine (DA) agonist nomifensine (NOM, 200 mg po), the DA receptor antagonist domperidone (DOM, 10 mg iv), TRH (200 \g=m\giv) and insulin (ITT, IU/kg iv). All patients were evaluated pre-surgery and 4 of them also post-surgery. Prl and GH were Over the past few years, a variety of dynamic tests have been devised or reappraised in prolactin (Prl) research (see Müller et al. 1981 , for review). The main objective of these maneuvers was to distin¬ guish between tumourous and non-tumourous hvperprolactinaemia and to advance under¬ standing on the mechanism(s) involved in the con¬ trol of Prl secretion. Some of these tests have also been used occasionally in other neuroendocrine disorders, such as acromegaly (Müller et (Fig. 1, up left) . Four of 12 pa¬ tients (cases 5, 6, 8 and 9) displayed a consistent Prl increase (149, 233, 271 and 237%, respectively) following TRH (Fig. 1, middle NOM (Fig. 1, up right) . In 2/8 patients (case 5 and 9), there was, as with TRH, an appreciable Prl increase after DOM (Fig. I, middle right patients, which suggests that neurotransmitters others than DA mediate the GH-releasing effect of the peptide (Casanueva et al. 1981a,c (Reichlin 1980 However, the TRH-induced GH rise may only be found in some acromegalie patients.
